Citations

Showing 10 of 108104 citations.

RETINAL INFILTRATION IN A CASE OF CHRONIC MYELOID LEUKEMIA
Yee, Claudine , Scruggs, Brittni A. , Scruggs, Brittni A , Flaxel, Christina J.

Mayo Clinic

RETINAL Cases & Brief Reports | April 6, 2022 | Volume: 17 | Issue: 6 | Pages: 690-693

10.1097/icb.0000000000001281 | PMID 35385433 Get It

Purpose: To describe a case of chronic myeloid leukemia with retinal leukemic infiltration identified by optical coherence tomography (OCT) and OCT angiography. Methods: Case report. Results: A 64-year-old man presented with bilateral painless blurred vision and three weeks of fatigue, unintentional weight loss, and complete hearing loss. Dilated fundus examination of both eyes showed peripheral intraretinal hemorrhages with white centers, vascular tortuosity, and peripheral nonperfusion. No macular lesions were identified by slit-lamp examination, fundus photography, fundus autofluorescence, or fluorescein angiography. Optical coherence tomography through the macula revealed multiple hyperreflective lesions throughout the inner retinal layers. Some of these lesions showed intrinsic flow by OCT angiography, but many lesions did not. The bone marrow biopsy confirmed chronic myeloid leukemia, and these intraretinal lesions were deemed to be leukemic infiltrates. The patient regained vision after systemic chemotherapy with resolution of the retinal infiltrates over time. Conclusion: Primary leukemic retinal involvement can be challenging to diagnose, especially when the macula appears normal clinically. Optical coherence tomography and OCT angiography are useful imaging modalities for the detection of retinal leukemic infiltration. Completing a thorough review of systems and initiating an urgent, systemic work-up are warranted in cases of retinal infiltration.
Long‐term oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients
McMillan, Ryan A. , Link, Michael J., Moore, Eric J. , Abel, Kathryn M. Van , O’Byrne, Jamie, Celda, María Peris, Foote, Robert L. , O'Byrne, Jamie, Chintakuntlawar, Ashish, Pinheiro Neto, Carlos D, Peris Celda, Maria, Van Abel, Kathryn M , McMillan, Ryan A , Gompel, Jamie J. Van , Price, Daniel L. , Giannini, Caterina , Chintakuntlawar, Ashish V. , Pinheiro‐Neto, Carlos , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | April 6, 2022 | Volume: 12 | Issue: 12 | Pages: 1457-1467

10.1002/alr.23007 | PMID 35385606 Get It

AbstractObjectiveEsthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory epithelium of the cribriform plate. The goal of this study was to update our oncologic outcomes for this disease and explore prognostic factors associated with survival.Materials and methodsWe performed a retrospective analysis of patients with ENB treated at a single tertiary care institution from January 1, 1960, to January 1, 2020. Univariate and multivariate analysis was performed. Overall survival (OS), progression‐free survival (PFS), and distant metastasis–free survival (DMFS) were reported.ResultsAmong 143 included patients, the 5‐year OS was 82.3% and the 5‐year PFS was 51.6%; 5‐year OS and PFS have improved in the modern era (2005–present). Delayed regional nodal metastasis was the most common site of recurrence in 22% of patients (median, 57 months). On univariate analysis, modified Kadish staging (mKadish) had a negative effect on OS, PFS, and DMFS (p < 0.05). Higher Hyams grade had a negative effect on PFS and DMFS (p < 0.05). Positive margin status had a negative effect on PFS (p < 0.05). Orbital invasion demonstrated worsening OS (hazard ratio, 3.1; p < 0.05). On multivariable analysis, high Hyams grade (3 or 4), high mKadish stage (C+D), and increasing age were independent negative prognostic factors for OS (p < 0.05). High Hyams grade (3+4), high mKadish stage (C+D), age, and positive margin status were independent negative prognostic factors for PFS (p < 0.05). High Hyams grade (3+4) was an independent negative prognostic factor for DMFS (p < 0.05).ConclusionsPatients with low Hyams grade and mKadish stage have favorable 5‐year OS, PFS, and DMFS.
P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
Popat, Rakesh , Badros, Ashraf , Kumar, Seema, Cohen, Alan R., Manier, Salomon , Voorhees, Peter M. , Rifkin, Robert M. , Martin, T., Jeng, Bennie H. , Lee, H, Berdeja, J. G., Jadhav, Vinay, Tosolini, A, Eliason, L, Palumbo, A, Trudel, S., Richardson, PG, Popat, Rakesh , Rodríguez‐Otero, Paula , Gay, Francesca , Chari, Ajai , Weisel, Katja C , Farooq, Asim V. , Chng, Wee Joo , Palumbo, Antonio , Dimopoulos, Meletios Α. , Lonial, Sagar , Terpos, Evangelos

Mayo Clinic

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 18-18

10.1097/01.hs9.0000829624.40467.0d Get It

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Gay, Francesca Maria, Berdeja, J. G., Stefano, V De, Hooper, B, Haltner, A, Kumar, S, Martin, T, Mateos, MV, Moreau, P, Rosta, E, Samjoo, IA, Usmani, S. Z., Weisel, K, Cc, Jackson, Olyslager, Y, Schecter, JM, Vogel, M, Garrett, A, Lee, S, Nesheiwat, T, Pacaud, L, Zhou, C, Valluri, S, Lin, Y, Hari, Parameswaran , Hooper, Becky , Rosta, Emily, Weisel, Katja C , Olyslager, Yunsi, Schecter, JM, Garrett, Ashraf, Lee, S, Nesheiwat, T, Pacaud, Lida , Costa, Luciano J. , Lin, Yi

Mayo Clinic

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 8-8

10.1097/01.hs9.0000829560.21894.ee Get It

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Popat, Rakesh , Hulin, Cyrille , Richardson, PG, Facon, T., Larsen, Jeremy T. , Minnema, M., Abdallah, Al-Ola, Badros, Ashraf , Knop, Stefan , Stadtmauer, Edward A. , Chen, M, Nguyen, Tiffany, Amin, Alpesh, Peluso, Teresa, Donk, Niels W.C.J. van de , Popat, Rakesh , Jagannath, Sundar , Oriol, Albert , Weisel, Katja C , Abdallah, Al-Ola , Lonial, Sagar

Mayo Clinic

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 14-15

10.1097/01.hs9.0000829600.37424.88 Get It

P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
Sonneveld, Pieter , Chanan‐Khan, A.A., Spicka, I, Munder, Markus , Mateos, MV, Mark, TM, Levin, M-D, Ahmadi, T., Qin, Xiang , Mayo, Wendy Garvin, Gai, X, Carey, Jodi, Carson, Robin, Spencer, Andrew , Weisel, Katja C , Nooka, Ajay K. , Masszi, Tamás , Beksaç, Meral , Spicka, I, Hungria, Vânia

Mayo Clinic

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 12-12

10.1097/01.hs9.0000829588.31575.a9 Get It

Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
Prabhu, Sujit S. , Rao, Ganesh , Laxton, Adrian W. , Fecci, Peter E. , O’Brien, Barbara , Sloan, Andrew E. , Chiang, Veronica , Mohammadi, Alireza M. , Chen, Clark, Sun, David, Sinicrope, Kaylyn, Campian, Jian , Kurz, Sylvia C. , Smith, Kris A. , Tovar-Spinoza, Zulma , Leuthardt, Eric C. , Khasraw, Mustafa , Fecci, Peter E , Groot, John de , Kim, Albert H. , Tatter, Stephen B. , Placantonakis, Dimitris G. , Strowd, Roy E. , Hadjipanayis, Costas G. , Khasraw, Mustafa , Piccioni, David Eric , Williams, Brian J.

Mayo Clinic

Neuro-Oncology Advances | April 6, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac040 | PMID 35611270 Get It

Abstract Background Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma. Methods Demographics, intraprocedural data, adverse events, KPS, health economics, and survival data were prospectively collected and then analyzed on IDH wild-type newly diagnosed and recurrent glioblastoma patients who were treated with laser ablation at 14 US centers between January 2016 and May 2019. Data were monitored for accuracy. Statistical analysis included individual variable summaries, multivariable differences in survival, and median survival numbers. Results A total of 29 new and 60 recurrent IDH wild-type WHO grade 4 glioblastoma patients were treated. Positive MGMT promoter methylation status was present in 5/29 of new and 23/60 of recurrent patients. Median physician-estimated extent of ablation was 91%-99%. Median overall survival (OS) was 9.73 months (95% confidence interval: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 months (6.94, 12.36) for recurrent patients. Median OS for newly diagnosed patients receiving post-LITT chemo/radiation was 16.14 months (6.11, not reached). Factors associated with improved survival were MGMT promoter methylation, adjuvant chemotherapy within 12 weeks, and tumor volume &lt;3 cc. Conclusions Laser ablation is a viable option for patients with new and recurrent glioblastoma. Median OS for IDH wild-type newly diagnosed glioblastoma is comparable to outcomes observed in other tumor resection studies when those patients undergo radiation and chemotherapy following LITT.
Swallowing Disorders in Patients with Chiari Malformation Type I After Decompression Neurosurgery
Oliveira, Luciana B. de, Queiroz, Moisés A. S. de, Filho, Leonardo de Macêdo , Otamendi-Lopez, Andrea, Barbosa, Priscilla Mayara Estrela , Filho, Euler N. Sauaia, de Macêdo Filho, Leonardo J M , Shlobin, Nathan A. , Porto, Andréa Cintia Laurindo

Mayo Clinic

No container title available | April 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1289761/v1 Get It

Abstract OBJECTIVE: The present study aimed to investigate postoperative swallowing disorders in patients diagnosed with CM I after decompression neurosurgery.METHODS: We selected 54 patients after decompression neurosurgery procedure for CM I from January 2017 to December 2019. We evaluated the speech-language assessment (CSLSA) 24-hours after post-surgical extubation. CSLSA observed aspects of posture, sensitivity, tone, and extra- and intraoral mobility of the FAO and visualizing the functions of breathing, phonation, articulation, chewing, and swallowing. We correlated the severity of the dysphagia and the presence of associated malformations in the CM I patients.RESULTS: In our study, 39 patients were female (mean age 41.3±47.1 years). Thirty-seven patients had associated malformations (p=0.0243): 21 patients syringomyelia, 11 basilar invagination and 5 syringomyelia and basilar invagination. Dysphagia was present in 37 of the cases (68.5%;p=0.0016). Dysphonia in 13 (24.1%;p=0.4785) and dysarthria in 3 (5.6%;p=0.0042). We observed in the CSLSA: orofacial hypomobility (29-patients–53.7%;p=0.0204), orofacial hyposensitivity (26-patients–48.1%; p=0.3023), reduced GAG reflex (24 patients–44.5%;p=0.1041), ineffective cough (19 patients–35.2%;p=0.0022), ineffective saliva swallowing (18-patients–33.3%;p=0.0396), dyspnea (13-patients–24.1%;p=0.4785), orofacial hypotonia (11-patients–20.4%;p=0.0004), altered cervical auscultation (10-patients–18.5%;p=0.0003), and dysarthria (3-patients–9.3%;p=0.0042). The presence of associated malformations significantly influenced the appearance of swallowing disorders, the severity of oropharyngeal dysphagia, the post-surgical complications (17-patients–31.5%;p<0.001), and the clinical outcomes (p=0.0029) of patients with CM type I. CONCLUSION: Decompressive neurosurgery for CM I had low rates of post-surgical complications overall. However, there was a high incidence of dysphagia. The presence of associated malformations is related with poorer prognosis and greater severity of oropharyngeal dysphagia in patients with CM I.
What Is the Role of Oligodendrocytes in Amyotrophic Lateral Sclerosis?
Benarroch, Eduardo E.

Mayo Clinic

Neurology | April 6, 2022 | Volume: 97 | Issue: 16 | Pages: 776-779

10.1212/wnl.0000000000012706 | PMID 34663738 Get It

Assessing the Role of High-Dose β-Agonists Use in Triggering Takotsubo Syndrome During Asthma Exacerbation
Abbasi, Danish , Faiek, Saif, Siddiqui, Waqas , López‐Candales, Angel , Siddiqui, Waqas J

Mayo Clinic

The Permanente Journal | April 6, 2022 | Volume: 26 | Issue: 1 | Pages: 99-105

10.7812/tpp/21.062 | PMID 35609166 Get It